Technical Analysis for GRAY - Graybug Vision, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.75 | -10.88% | -0.58 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | N/A | Down | Down |
| Historical GRAY trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -10.88% | |
| Narrow Range Bar | Range Contraction | -10.88% | |
| NR7 | Range Contraction | -10.88% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 10% | about 4 hours ago |
| Trending on StockTwits | about 7 hours ago |
| 60 Minute Opening Range Breakdown | about 7 hours ago |
| 1.5x Volume Pace | about 7 hours ago |
| Down 5% | about 7 hours ago |
Get a Trading Sidekick!
- Earnings date: ???
Graybug Vision, Inc. Description
Graybug Vision, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is based in Redwood City, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Diseases Macular Degeneration Ophthalmology Related Macular Degeneration Retina Glaucoma Nerve Diabetic Retinopathy Macular Edema Blindness Wet Age Related Macular Degeneration Diabetic Macular Edema Retinopathy Intravitreal Administration Macula Of Retina Intravitreal Injection
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 37.88 |
| 52 Week Low | 4.62 |
| Average Volume | 618,281 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 16.13 |
| 20-Day Moving Average | 6.35 |
| 10-Day Moving Average | 5.47 |
| Average True Range | 0.91 |
| ADX | 63.93 |
| +DI | 8.32 |
| -DI | 40.84 |
| Chandelier Exit (Long, 3 ATRs ) | 5.99 |
| Chandelier Exit (Short, 3 ATRs ) | 7.35 |
| Upper Bollinger Band | 8.52 |
| Lower Bollinger Band | 4.18 |
| Percent B (%b) | 0.13 |
| BandWidth | 68.36 |
| MACD Line | -2.82 |
| MACD Signal Line | -3.39 |
| MACD Histogram | 0.5669 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.81 | ||||
| Resistance 3 (R3) | 5.88 | 5.60 | 5.63 | ||
| Resistance 2 (R2) | 5.60 | 5.33 | 5.57 | 5.57 | |
| Resistance 1 (R1) | 5.18 | 5.17 | 5.04 | 5.10 | 5.51 |
| Pivot Point | 4.90 | 4.90 | 4.83 | 4.86 | 4.90 |
| Support 1 (S1) | 4.47 | 4.63 | 4.33 | 4.40 | 3.99 |
| Support 2 (S2) | 4.19 | 4.46 | 4.16 | 3.93 | |
| Support 3 (S3) | 3.77 | 4.19 | 3.87 | ||
| Support 4 (S4) | 3.69 |
